Topcon
7732
TEMONA
3985
Forside
2330
Okamoto Glass
7746
Delta-Fly Pharma
4598
(FY)Sep 30, 2024 | (Q2)Mar 31, 2024 | (Q1)Dec 31, 2023 | (FY)Sep 30, 2023 | (Q4)Sep 30, 2023 | (Q3)Jun 30, 2023 | (Q2)Mar 31, 2023 | (Q1)Dec 31, 2022 | (FY)Sep 30, 2022 | (Q4)Sep 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 31.19%18.14B | 35.06%5.55B | 86.63%3.68B | 28.89%13.83B | 30.55%4.69B | 59.21%3.05B | 43.78%4.11B | -16.38%1.97B | 18.74%10.73B | 3.6B |
Cost of revenue | 42.58%6.53B | 45.44%1.97B | 76.69%1.28B | 28.25%4.58B | 26.44%1.46B | 56.14%1.04B | 41.32%1.36B | -8.45%722.96M | 7.88%3.57B | 1.16B |
Gross profit | 25.55%11.61B | 29.96%3.58B | 92.39%2.4B | 29.21%9.25B | 32.50%3.23B | 60.84%2.01B | 45.01%2.76B | -20.38%1.25B | 25.01%7.16B | 2.44B |
Operating expense | 19.59%4.84B | -5.20%1.22B | 53.06%1.05B | 37.94%4.05B | 19.65%975.53M | 69.53%1.09B | 61.17%1.29B | 2.25%687.95M | 28.97%2.93B | 815.34M |
Operating profit | 30.18%6.77B | 60.88%2.36B | 140.79%1.35B | 23.15%5.2B | 38.96%2.25B | 51.64%921.28M | 33.27%1.47B | -37.43%558.92M | 22.40%4.22B | 1.62B |
Net non-operating interest income (expenses) | -81.46%1.62M | -98.38%91K | -99.14%26K | 4,873.30%8.75M | 42.86%80K | 10.71%31K | 8,274.63%5.61M | 12,024.00%3.03M | -94.82%176K | 56K |
Non-operating interest income | -81.46%1.62M | -98.38%91K | -99.14%26K | 4,873.30%8.75M | 42.86%80K | 10.71%31K | 8,274.63%5.61M | 12,024.00%3.03M | -94.82%176K | --56K |
Net investment income | 75.19%3.53M | 0 | 16.80%1.46M | 492.65%2.02M | 0 | 765K | 0 | 1.25M | -15.00%340K | 0 |
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | -104.37%-48.55M | -628.56%-104.61M | 51.23%-1.84M | -23.76M | 0 | -5.62M | -14.36M | -3.78M | 0 | 0 |
Income from associates and other participating interests | ||||||||||
Special income (charges) | ||||||||||
Other non-operating income (expenses) | -77.43%1.52M | -78.85%550K | -201.76%-750K | 316.27%6.73M | -9.77%600K | 365.00%2.79M | 751.63%2.6M | -1.73%737K | -92.15%1.62M | 665K |
Income before tax | 29.53%6.73B | 54.44%2.26B | 140.06%1.34B | 22.94%5.2B | 38.94%2.26B | 51.06%919.24M | 32.75%1.46B | -37.34%560.17M | 23.93%4.23B | 1.62B |
Income tax | 33.59%1.78B | 53.94%720.64M | 138.37%440.04M | 5.14%1.33B | -9.35%378.52M | 47.72%297.9M | 31.94%468.14M | -36.36%184.6M | 24.58%1.26B | 417.55M |
Net income | 28.14%4.96B | 54.67%1.54B | 140.89%904.71M | 30.53%3.87B | 55.67%1.88B | 52.71%621.34M | 33.13%992.79M | -37.82%375.57M | 23.65%2.96B | 1.21B |
Net income continuous operations | 28.14%4.96B | 54.67%1.54B | 140.89%904.71M | 30.53%3.87B | 55.67%1.88B | 52.71%621.34M | 33.13%992.79M | -37.82%375.57M | 23.65%2.96B | --1.21B |
Noncontrolling interests | ||||||||||
Net income attributable to the company | 28.14%4.96B | 54.67%1.54B | 140.89%904.71M | 30.53%3.87B | 55.67%1.88B | 52.71%621.34M | 33.13%992.79M | -37.82%375.57M | 23.65%2.96B | 1.21B |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | 28.14%4.96B | 54.67%1.54B | 140.89%904.71M | 30.53%3.87B | 55.67%1.88B | 52.71%621.34M | 33.13%992.79M | -37.82%375.57M | 23.65%2.96B | 1.21B |
Gross dividend payment | ||||||||||
Basic earnings per share | 28.08%258.04 | 54.59%79.97 | 140.48%47.11 | 29.78%201.46 | 54.69%97.78 | 51.07%32.36 | 32.54%51.73 | -37.95%19.59 | 23.86%155.23 | 63.21 |
Diluted earnings per share | 28.08%258.04 | 54.58%79.9666 | 140.48%47.11 | 30.27%201.46 | 55.14%97.7536 | 51.50%32.36 | 33.08%51.73 | -37.63%19.59 | 24.04%154.65 | 63.01 |
Dividend per share | 78.43%91 | 0 | 0 | 27.50%51 | 27.50%51 | 0 | 0 | 0 | 40 | 40 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |